Dawson James Reiterates Buy Rating on Lineage Cell Therapeutics Inc. (LCTX), Dry AMD Remains Key Opportunity
Tweet Send to a Friend
Dawson James analyst Jason Kolbert reiterated a Buy rating and $6.00 price target on Lineage Cell Therapeutics Inc. (NYSE: LCTX)The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
